Global MRI-guided Radiation Therapy Systems Market Size, Trends & Growth Opportunity By System Type, By Magnetic Field Strength, By Treatment Modality, By End User, By Region and Forecast Till 2030

Report ID : AMR1006258 | Industries : Healthcare | Published On :October 2026 | Page Count : 274

Request Sample
Ask for Customization

MRI-Guided Radiation Therapy Systems Market Overview and Definition

The global MRI-guided radiation therapy systems market covers radiotherapy delivery platforms that integrate magnetic resonance imaging with the treatment unit, together with the planning, adaptive workflow, software and service layers that surround them, supplied to radiation oncology departments worldwide.

This report describes the category strictly as a market segment, making no claim about clinical performance, safety, efficacy or patient outcome for any system, technique or company, and it describes FDA, CE and radiation safety schemes only as market-access categories.

It excludes standalone diagnostic MRI scanners, conventional CT-guided linear accelerators and particle therapy as standalone categories, because the defining feature of this category is MRI imaging integrated with radiation delivery.

Ten segmentation dimensions appear in this report. The first describes system type across five categories: MRI-guided linear accelerator (MR-Linac) systems, hybrid MRI-radiotherapy platforms, MRI-guided stereotactic radiotherapy systems, adaptive radiation therapy platforms and MRI-integrated treatment planning ecosystems. The second describes magnetic field strength across low-field, mid-field and high-field systems.

Treatment modality spans external beam radiation therapy, stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS), hypofractionated radiotherapy and adaptive fractionated therapy, while the application dimension covers eight treatment site categories: prostate, pancreatic, lung, liver, brain, gynecologic, head and neck, and pediatric oncology.

Workflow capability covers six categories: online adaptive radiotherapy, real-time tumor tracking, automated contouring, artificial intelligence (AI) assisted planning, motion management integration and daily adaptive replanning. The software and informatics dimension covers treatment planning software, oncology information systems, AI-driven contouring platforms, imaging analytics platforms and cloud-connected oncology workflows.

The remaining dimensions describe the buying side: six end user types, four procurement models, six service categories and four regulatory and certification alignment categories that are treated purely as market-access categories. Geographic coverage spans North America, Europe and Asia-Pacific, with thirteen countries named.

What separates the category from conventional image-guided radiotherapy is that the MRI unit is part of the delivery platform. A single capital purchase therefore carries a magnet, a delivery unit, planning software and a long-term service relationship, which is why buying decisions bring physics, oncology, procurement and facilities teams to the same table.

Market Size & Growth Forecast (2026 to 2030)

The global MRI-guided radiation therapy systems market is estimated at approximately USD 0.40 Billion in 2025 and is projected to reach approximately USD 0.70 Billion by 2030, expanding at a compound annual growth rate of roughly 12 percent.

The estimate covers MRI-guided radiation therapy systems together with their planning, software integration and service categories as supplied to radiation oncology departments, and excludes standalone diagnostic MRI scanners, conventional CT-guided linear accelerators and particle therapy.

Growth is led by adaptive radiation therapy platforms and MRI-integrated treatment planning ecosystems, which expand faster than the hardware base because software, contouring and replanning tools are added to installed platforms, while MR-Linac systems remain the largest system type by value. The estimate is a derivation from the wider radiotherapy category, set out in the Research Methodology section, and is built on labelled analyst assumptions.

Metric Value
Market Size (2025) Approximately USD 0.40 Billion
Forecast Size (2030) Approximately USD 0.70 Billion
CAGR (2025-2030) Approximately 12%
Base Year 2025
Forecast Period 2026-2030 (5-year)
Scope Note MRI-guided radiation therapy systems with their planning, software integration and service categories only; excludes standalone diagnostic MRI scanners, conventional CT-guided linear accelerators and particle therapy
Largest System Type MRI-guided linear accelerator (MR-Linac) systems
Fastest-Growing System Type Adaptive radiation therapy platforms and MRI-integrated treatment planning ecosystems
Largest Treatment Modality External beam radiation therapy
Fastest-Growing Treatment Modality Adaptive fractionated therapy
Largest End User Category Academic medical centers and comprehensive cancer centers
Fastest-Growing Workflow Capability AI-assisted planning and automated contouring
Largest Regional Concentration North America
Fastest-Growing Region Asia-Pacific

 

MARKET SHIFT

Value is shifting from the magnet and delivery unit toward the software and service layer around them, as installed platforms receive contouring, replanning and informatics upgrades that extend their useful life and widen the set of programs that can use them.

 

Market Drivers

Growing interest in online adaptive radiotherapy keeps MRI-guided delivery platforms on the capital agenda of radiation oncology departments, because the category pairs imaging at the treatment couch with the ability to revisit a treatment plan at each session.

Expansion of stereotactic and hypofractionated treatment programs places a premium on imaging and motion management at the point of delivery, which supports specification of MRI-guided stereotactic systems and adaptive fractionated programs.

Rising adoption of AI-assisted contouring and planning software widens the set of centers able to consider adaptive treatment, because it reduces the staff effort that an adaptive session otherwise demands and extends demand into software upgrades for installed platforms.

Investment by academic centers, comprehensive cancer centers and precision oncology networks in reference-site technology sustains demand, since these institutions use advanced platforms to support research participation, clinical trial activity and program differentiation.

Because a platform purchase is followed by years of software upgrades, remote diagnostics, preventive maintenance and training, installed base growth also builds a recurring service and software revenue stream that supports supplier investment in the category.

Market Restraints

The high capital cost of MRI-guided radiotherapy systems, together with vault, shielding and magnet infrastructure requirements, concentrates adoption in well-funded centers and slows entry by smaller operators.

Procurement cycles of 9 to 24 months, driven by clinical evaluation, technical validation, budget approval and committee review, delay the conversion of interest into installed systems and make supplier revenue timing uneven.

Reimbursement uncertainty and budget constraints make the business case for adaptive workflows harder to settle for mid-sized operators, which limits the speed at which adoption spreads beyond academic and comprehensive cancer centers.

The workflow and staffing demands of adaptive sessions, including physics and physician time, limit throughput at many centers, so some buyers defer adoption until automation tools reduce that burden.

Technology obsolescence risk, meaning the possibility that a platform bought today is overtaken by software or hardware advances, also lengthens evaluation and raises the weight buyers place on a supplier's upgrade roadmap.

PROCUREMENT INSIGHT

The restraints are mostly about timing and affordability rather than demand, which is why partnership, leasing and managed equipment structures matter: they change when and how a center pays without changing what it buys.

 

Market Opportunities

Considerable untapped opportunities exist across emerging oncology regions and mid-tier cancer centers not yet served by MRI-guided platforms, where radiation oncology capacity is expanding and few centers have yet specified an MRI-guided system.

AI-assisted workflow differentiation is a second opportunity, because automated contouring and replanning can lower the effort of adaptive sessions and so widen the base of centers able to run them.

Service and training expansion offers a recurring opportunity, spanning remote diagnostics, software upgrades, clinical workflow consulting and training and certification services bought alongside or after the platform.

Partnership-led adoption through academic collaborations, clinical research alliances and long-term oncology infrastructure partnerships gives suppliers a route into centers that would not otherwise fund a platform on a conventional capital cycle.

Cloud-connected oncology workflows and imaging analytics platforms add a further software opportunity, since they extend the value of each installed system beyond the treatment room.

MRI-Guided Radiotherapy System Types and Magnetic Field Strength

Buyers comparing MR-Linac and hybrid platform types weigh how imaging and delivery are integrated alongside the magnet class, since MR-Linac, hybrid MRI-radiotherapy, MRI-guided stereotactic, adaptive and planning ecosystem systems are each offered in low-field, mid-field or high-field configurations.

Platform architecture and magnet class are read together because each constrains the other: the magnet class shapes the room, shielding and service arrangements, while the system type shapes which treatment programs the platform is specified for.

MR-Linac systems form the largest system type by value, with adaptive radiation therapy platforms and MRI-integrated treatment planning ecosystems forming the fastest-growing group as software content rises.

Treatment Modalities and Tumor Site Applications

Demand also follows the programs a center runs, and treatment modalities and site categories such as external beam, stereotactic body, stereotactic radiosurgery, hypofractionated and adaptive fractionated delivery shape which platform is specified.

External beam radiation therapy is the largest treatment modality, and adaptive fractionated therapy is the fastest-growing, reflecting the shift toward sessions that are replanned from the imaging acquired on the day.

The eight treatment site categories, from prostate, pancreatic, lung and liver to brain, gynecologic, head and neck, and pediatric oncology, are tracked in this report as application categories only, with no statement about outcomes for any site.

Adaptive Workflow Capabilities and Software Integration

How a platform is used day to day depends heavily on adaptive workflow and planning software, including the contouring, tracking and replanning tools that determine how an adaptive session runs and how much staff time it needs.

The software and informatics layer spans treatment planning software, oncology information systems, AI-driven contouring platforms, imaging analytics platforms and cloud-connected oncology workflows, and it is the part of the category that changes fastest after installation.

AI-assisted planning and automated contouring are the fastest-growing workflow capabilities, because they address the staffing demand that restrains broader adoption of adaptive sessions.

End Users, Procurement and Service Models

Who buys and how they buy is mapped through end users and procurement models, from academic medical centers and comprehensive cancer centers to multi-site oncology networks, and from direct capital purchase to leasing, vendor-managed service contracts and long-term infrastructure partnerships.

Academic medical centers and comprehensive cancer centers form the largest end user category, and procurement in the category is typically a long-cycle capital decision shaped by tender requirements, clinical evaluation periods and committee review.

Six service categories, from installation and commissioning to training and certification services, are bought alongside the platform rather than after it, which is why service capability weighs heavily in supplier selection.

MRI-Guided Radiation Therapy Systems Market, By Region

This report covers North America, Europe and Asia-Pacific, reflecting where advanced radiation oncology investment is concentrated. Thirteen countries are named across the three regions.

North America forms the largest regional concentration in this report, covered through the United States and Canada, including states and provinces such as Ohio, California, Texas, New York, Massachusetts, Florida, Ontario and Quebec, with demand concentrated in academic oncology networks, large integrated hospital systems and private oncology centers.

Europe is covered through the United Kingdom, Germany, the Netherlands, France, Italy and Switzerland, with precision oncology centers in cities such as London, Manchester, Heidelberg, Munich, Amsterdam, Utrecht, Paris, Lyon, Milan and Zurich forming the demand base.

Asia-Pacific forms the fastest-growing regional concentration, covered through China, Japan, South Korea, India and Australia, with tertiary cancer hospitals in cities such as Beijing, Shanghai, Tokyo, Osaka, Seoul, Delhi NCR, Mumbai, Bengaluru, Sydney and Melbourne driving new system specification.

Demand is shaped by the way radiation oncology capacity is funded in each region, from tender-based and public-private procurement frameworks to private operator capital budgets and government cancer institute programs.

Regional sizing, growth rates and country-level breakdowns are reserved for the full report rather than presented on this page.

REGIONAL OPPORTUNITY

Asia-Pacific combines expanding tertiary cancer hospital capacity with a small installed base of MRI-guided platforms, so the opportunity lies in centers specifying their first system rather than in replacement demand, which is the pattern in the most established regions.

 

Leading Companies

ViewRay Systems, Inc., Elekta, Siemens Healthineers, GE HealthCare, Philips, Varian Medical Systems, Accuray Incorporated, Canon Medical Systems, Brainlab, RaySearch Laboratories, IBA Radiopharma Solutions, Mevion Medical Systems, Panacea Medical Technologies, Hitachi High-Tech, Fujifilm Healthcare and Shimadzu Corporation are covered in the full report, listed in no particular order. How the landscape is framed is set out in the supplier landscape overview for this category.

Beyond This Page

The full report extends well past the segmentation summarised here and into the commercial detail that shapes how MRI-guided radiotherapy supply is actually won.

Buyer intelligence maps demand by buyer segment, buyer industry and organization type, regional demand clusters, buyer scale, procurement model, key buying triggers, decision-maker roles, budget ownership, vendor selection criteria, contract value bands and sales cycle length.

Competitive benchmarking compares suppliers across installed system base, geographic deployment footprint, clinical partnership ecosystem, treatment planning capabilities, service infrastructure strength, research collaboration intensity, software innovation and regulatory approvals, alongside strategic moves such as clinical collaborations, AI integration partnerships, hospital deployment agreements and precision oncology investments.

The market playbook covers cost structure, installation and infrastructure costs, service contract economics, software licensing models, compliance and regulatory shifts, customer buying behavior, channel and distribution evolution, technology disruptions and market risks.

Procurement chapters cover buyer and supplier power, the procurement lifecycle from clinical evaluation to commissioning, and total cost of ownership including infrastructure, training, upgrade and maintenance considerations, and go-to-market chapters cover entry pathways, distributor and partner mapping, market-access routes and trade fairs and industry platforms.

Company profiles cover sixteen companies across overview, ownership, geographic footprint, MRI-guided radiotherapy portfolio, oncology imaging capabilities, adaptive radiotherapy offerings, AI and software capabilities, clinical target segments, distribution strategy, partnerships, R&D initiatives and further fields.

Frequently Asked Questions

The market is estimated at approximately USD 0.40 Billion in 2025 and is projected to reach approximately USD 0.70 Billion by 2030, expanding at a compound annual growth rate of roughly 12 percent. The estimate is a derivation from the wider radiotherapy category using labelled analyst assumptions.

They are radiotherapy delivery platforms that integrate magnetic resonance imaging with the treatment unit, together with the planning, adaptive workflow, software and service layers around them. This report describes the category strictly as a market segment and makes no claim about the performance or outcomes of any system.

Five system types are tracked: MR-Linac systems, hybrid MRI-radiotherapy platforms, MRI-guided stereotactic radiotherapy systems, adaptive radiation therapy platforms and MRI-integrated treatment planning ecosystems, each assessed across low-field, mid-field and high-field configurations.

North America forms the largest regional concentration, while Asia-Pacific forms the fastest-growing, tied to expanding tertiary cancer hospital capacity and first-time system specification. Europe is the third region covered.

Growth is driven by interest in online adaptive radiotherapy, expansion of stereotactic and hypofractionated programs, wider use of AI-assisted contouring and planning software, and investment by academic and comprehensive cancer centers in reference-site technology.

The main restraints are high capital cost and infrastructure requirements, procurement cycles of 9 to 24 months, reimbursement uncertainty and budget constraints, and the workflow and staffing demands of adaptive sessions.

Buyers are mainly academic medical centers, comprehensive cancer centers, university hospitals, specialty radiation oncology clinics, multi-site oncology networks and research institutions, purchasing through direct capital purchase, leasing, vendor-managed service contracts or long-term infrastructure partnerships.

They are the three magnetic field strength categories used to segment systems by the magnet class their platform is built around. They are applied as market categories only, and this report makes no comparison of image quality or treatment performance between them.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Global MRI-guided Radiation Therapy Systems Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Growing Interest in Online Adaptive Radiotherapy, Where Daily Soft-Tissue Imaging Allows a Treatment Plan to Be Revisited at Each Session, Which Keeps MRI-Guided Delivery Platforms on the Capital Agenda of Radiation Oncology Departments.

3.3.2. Expansion of Stereotactic and Hypofractionated Treatment Programs, Which Place a Premium on Imaging and Motion Management at the Point of Delivery.

3.3.3. Rising Adoption of AI-Assisted Contouring and Planning Software, Which Shortens the Adaptive Workflow and Widens the Set of Centers Able to Consider Adaptive Treatment.

3.3.4. Investment by Academic Centers, Comprehensive Cancer Centers and Precision Oncology Networks in Reference-Site Technology That Supports Research Participation and Program Differentiation.

3.4. Restraints

3.4.1. High Capital Cost of MRI-Guided Radiotherapy Systems, Together with Vault, Shielding and Magnet Infrastructure Requirements, Which Concentrates Adoption in Well-Funded Centers.

3.4.2. Long Procurement Cycles of 9 to 24 Months Driven by Clinical Evaluation, Budget Approval and Committee Review.

3.4.3. Reimbursement Uncertainty and Budget Constraints, Which Make the Business Case for Adaptive Workflows Harder to Settle for Mid-Sized Operators.

3.4.4. Workflow and Staffing Demands of Adaptive Sessions, Including Physics and Physician Time, Which Limit Throughput for Many Centers.

3.5. Opportunities

3.5.1. Considerable Untapped Opportunity Identified in the Report Competitive Mapping Across Emerging Oncology Markets and Mid-Tier Cancer Centers Not Yet Served by MRI-Guided Platforms.

3.5.2. AI-Assisted Workflow Differentiation, Where Automated Contouring and Replanning Can Lower the Effort of Adaptive Sessions.

3.5.3. Service and Training Expansion, Including Remote Diagnostics, Software Upgrades and Clinical Workflow Consulting.

3.5.4. Partnership-Led Adoption Through Academic Collaborations, Clinical Research Alliances and Long-Term Oncology Infrastructure Partnerships.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. System Type

4.1. MRI-Guided Linear Accelerator (MR-Linac) Systems

4.2. Hybrid MRI-Radiotherapy Platforms

4.3. MRI-Guided Stereotactic Radiotherapy Systems

4.4. Adaptive Radiation Therapy Platforms

4.5. MRI-Integrated Treatment Planning Ecosystems

5. Magnetic Field Strength

5.1. Low-Field MRI-Guided Systems

5.2. Mid-Field MRI-Guided Systems

5.3. High-Field MRI-Guided Systems

6. Treatment Modality

6.1. External Beam Radiation Therapy

6.2. Stereotactic Body Radiation Therapy (SBRT)

6.3. Stereotactic Radiosurgery (SRS)

6.4. Hypofractionated Radiotherapy

6.5. Adaptive Fractionated Therapy

7. Clinical Application

7.1. Prostate Cancer Treatment

7.2. Pancreatic Cancer Treatment

7.3. Lung Cancer Treatment

7.4. Liver Cancer Treatment

7.5. Brain Tumor Treatment

7.6. Gynecologic Oncology

7.7. Head and Neck Oncology

7.8. Pediatric Oncology

8. Workflow Capability

8.1. Online Adaptive Radiotherapy

8.2. Real-Time Tumor Tracking

8.3. Automated Contouring

8.4. AI-Assisted Planning

8.5. Motion Management Integration

8.6. Daily Adaptive Replanning

9. End User

9.1. Academic Medical Centers

9.2. Comprehensive Cancer Centers

9.3. University Hospitals

9.4. Specialty Radiation Oncology Clinics

9.5. Multi-Site Oncology Networks

9.6. Research Institutions

10. Procurement Model

10.1. Direct Capital Purchase

10.2. Leasing and Managed Equipment Agreements

10.3. Vendor-Managed Service Contracts

10.4. Long-Term Oncology Infrastructure Partnerships

11. Service Category

11.1. Installation and Commissioning

11.2. Software Upgrades

11.3. Clinical Workflow Consulting

11.4. Preventive Maintenance

11.5. Remote Diagnostics

11.6. Training and Certification Services

12. Software and Informatics Integration

12.1. Treatment Planning Software

12.2. Oncology Information Systems

12.3. AI-Driven Contouring Platforms

12.4. Imaging Analytics Platforms

12.5. Cloud-Connected Oncology Workflows

13. Regulatory and Certification Alignment

13.1. FDA-Approved Systems

13.2. CE-Certified Systems

13.3. Regional Radiation Safety Compliance

13.4. Hospital Accreditation-Linked Procurement

14. Buyer Intelligence and Demand Landscape

14.1. Buyer Segmentation

14.1.1. Academic Oncology Networks

14.1.2. Large Integrated Hospital Systems

14.1.3. Private Oncology Centers

14.1.4. Government Cancer Institutes

14.1.5. Research-Led Treatment Facilities

14.2. Buyer Industries

14.2.1. Oncology Healthcare Systems

14.2.2. Specialty Radiology Centers

14.2.3. University Medical Research

14.2.4. Precision Medicine Programs

14.3. Buyer Company Types

14.3.1. Public Hospitals

14.3.2. Private Healthcare Operators

14.3.3. Academic Healthcare Institutions

14.3.4. Nonprofit Cancer Centers

14.3.5. Multi-Location Oncology Groups

14.4. Regional Demand Clusters

14.4.1. Advanced Oncology Hubs in North America

14.4.2. European Precision Oncology Centers

14.4.3. Asia-Pacific Tertiary Cancer Hospitals

14.4.4. High-Investment Radiation Therapy Corridors

14.5. Buyer Scale Classification

14.5.1. Enterprise Hospital Networks

14.5.2. Mid-Sized Specialty Oncology Operators

14.5.3. Single-Site Advanced Cancer Treatment Centers

14.6. Procurement Models

14.6.1. Tender-Based Acquisition

14.6.2. Clinical Evaluation Procurement

14.6.3. Long-Cycle Capital Budgeting

14.6.4. Public-Private Procurement Frameworks

14.7. Key Buying Triggers

14.7.1. Need for Adaptive Treatment Precision

14.7.2. Expansion of Radiation Oncology Capabilities

14.7.3. Reduction in Collateral Tissue Damage

14.7.4. Competitive Differentiation for Cancer Centers

14.7.5. Clinical Trial Participation Requirements

14.8. Decision-Maker Roles

14.8.1. Chief Science Officers

14.8.2. Radiation Oncology Directors

14.8.3. Chief Medical Officers

14.8.4. Hospital Procurement Heads

14.8.5. Oncology Physicists

14.8.6. Clinical Technology Committees

14.9. Budget Ownership

14.9.1. Oncology Departments

14.9.2. Hospital Executive Boards

14.9.3. Research Funding Programs

14.9.4. Government Healthcare Initiatives

14.10. Vendor Selection Criteria

14.10.1. Clinical Validation

14.10.2. MRI Integration Quality

14.10.3. Treatment Accuracy

14.10.4. Workflow Efficiency

14.10.5. Service Infrastructure

14.10.6. Upgrade Roadmap

14.10.7. AI Functionality

14.10.8. Regulatory Compliance

14.11. Contract Value Bands

14.11.1. High-Value Capital Infrastructure Procurement

14.11.2. Multi-Year Service Agreements

14.11.3. Enterprise Oncology Transformation Projects

14.12. Sales Cycle Length

14.12.1. 9-24 Month Enterprise Procurement Cycles

14.12.2. Clinical Evaluation Periods

14.12.3. Regulatory and Installation Approvals

14.13. Strategic Relevance for ViewRay Systems

14.13.1. Positioning in Adaptive Radiotherapy Leadership

14.13.2. Competitive Differentiation Through MR-Linac Technology

14.13.3. Expansion into Precision Oncology Networks

14.13.4. Growth via AI-Enabled Treatment Workflows

15. By Region

15.1. North America

15.2. Europe

15.3. Asia-Pacific

16. North America Market Analysis and Forecast (2026–2030)

16.1. Introduction

16.2. Market Share Analysis

16.3. Market Size and Forecast

16.4. Market Size and Forecast, By Geography

16.4.1. United States

16.4.1.1. Market Share Analysis

16.4.1.2. Market Size and Forecast

16.4.1.3. By Product

16.4.1.4. By Technology

16.4.1.5. By Application

16.4.1.6. By Customer

16.4.1.7. Ohio

16.4.1.7.1. Market Share Analysis

16.4.1.7.2. Market Size and Forecast

16.4.1.7.3. By Product

16.4.1.7.4. By Technology

16.4.1.7.5. By Application

16.4.1.7.6. By Customer

16.4.1.8. California

16.4.1.8.1. Market Share Analysis

16.4.1.8.2. Market Size and Forecast

16.4.1.8.3. By Product

16.4.1.8.4. By Technology

16.4.1.8.5. By Application

16.4.1.8.6. By Customer

16.4.1.9. Texas

16.4.1.9.1. Market Share Analysis

16.4.1.9.2. Market Size and Forecast

16.4.1.9.3. By Product

16.4.1.9.4. By Technology

16.4.1.9.5. By Application

16.4.1.9.6. By Customer

16.4.1.10. New York

16.4.1.10.1. Market Share Analysis

16.4.1.10.2. Market Size and Forecast

16.4.1.10.3. By Product

16.4.1.10.4. By Technology

16.4.1.10.5. By Application

16.4.1.10.6. By Customer

16.4.1.11. Massachusetts

16.4.1.11.1. Market Share Analysis

16.4.1.11.2. Market Size and Forecast

16.4.1.11.3. By Product

16.4.1.11.4. By Technology

16.4.1.11.5. By Application

16.4.1.11.6. By Customer

16.4.1.12. Florida

16.4.1.12.1. Market Share Analysis

16.4.1.12.2. Market Size and Forecast

16.4.1.12.3. By Product

16.4.1.12.4. By Technology

16.4.1.12.5. By Application

16.4.1.12.6. By Customer

16.4.2. Canada

16.4.2.1. Market Share Analysis

16.4.2.2. Market Size and Forecast

16.4.2.3. By Product

16.4.2.4. By Technology

16.4.2.5. By Application

16.4.2.6. By Customer

16.4.2.7. Ontario

16.4.2.7.1. Market Share Analysis

16.4.2.7.2. Market Size and Forecast

16.4.2.7.3. By Product

16.4.2.7.4. By Technology

16.4.2.7.5. By Application

16.4.2.7.6. By Customer

16.4.2.8. Quebec

16.4.2.8.1. Market Share Analysis

16.4.2.8.2. Market Size and Forecast

16.4.2.8.3. By Product

16.4.2.8.4. By Technology

16.4.2.8.5. By Application

16.4.2.8.6. By Customer

17. Europe Market Analysis and Forecast (2026–2030)

17.1. Introduction

17.2. Market Share Analysis

17.3. Market Size and Forecast

17.4. Market Size and Forecast, By Geography

17.4.1. United Kingdom

17.4.1.1. Market Share Analysis

17.4.1.2. Market Size and Forecast

17.4.1.3. By Product

17.4.1.4. By Technology

17.4.1.5. By Application

17.4.1.6. By Customer

17.4.1.7. London

17.4.1.7.1. Market Share Analysis

17.4.1.7.2. Market Size and Forecast

17.4.1.7.3. By Product

17.4.1.7.4. By Technology

17.4.1.7.5. By Application

17.4.1.7.6. By Customer

17.4.1.8. Manchester

17.4.1.8.1. Market Share Analysis

17.4.1.8.2. Market Size and Forecast

17.4.1.8.3. By Product

17.4.1.8.4. By Technology

17.4.1.8.5. By Application

17.4.1.8.6. By Customer

17.4.2. Germany

17.4.2.1. Market Share Analysis

17.4.2.2. Market Size and Forecast

17.4.2.3. By Product

17.4.2.4. By Technology

17.4.2.5. By Application

17.4.2.6. By Customer

17.4.2.7. Heidelberg

17.4.2.7.1. Market Share Analysis

17.4.2.7.2. Market Size and Forecast

17.4.2.7.3. By Product

17.4.2.7.4. By Technology

17.4.2.7.5. By Application

17.4.2.7.6. By Customer

17.4.2.8. Munich

17.4.2.8.1. Market Share Analysis

17.4.2.8.2. Market Size and Forecast

17.4.2.8.3. By Product

17.4.2.8.4. By Technology

17.4.2.8.5. By Application

17.4.2.8.6. By Customer

17.4.3. Netherlands

17.4.3.1. Market Share Analysis

17.4.3.2. Market Size and Forecast

17.4.3.3. By Product

17.4.3.4. By Technology

17.4.3.5. By Application

17.4.3.6. By Customer

17.4.3.7. Amsterdam

17.4.3.7.1. Market Share Analysis

17.4.3.7.2. Market Size and Forecast

17.4.3.7.3. By Product

17.4.3.7.4. By Technology

17.4.3.7.5. By Application

17.4.3.7.6. By Customer

17.4.3.8. Utrecht

17.4.3.8.1. Market Share Analysis

17.4.3.8.2. Market Size and Forecast

17.4.3.8.3. By Product

17.4.3.8.4. By Technology

17.4.3.8.5. By Application

17.4.3.8.6. By Customer

17.4.4. France

17.4.4.1. Market Share Analysis

17.4.4.2. Market Size and Forecast

17.4.4.3. By Product

17.4.4.4. By Technology

17.4.4.5. By Application

17.4.4.6. By Customer

17.4.4.7. Paris

17.4.4.7.1. Market Share Analysis

17.4.4.7.2. Market Size and Forecast

17.4.4.7.3. By Product

17.4.4.7.4. By Technology

17.4.4.7.5. By Application

17.4.4.7.6. By Customer

17.4.4.8. Lyon

17.4.4.8.1. Market Share Analysis

17.4.4.8.2. Market Size and Forecast

17.4.4.8.3. By Product

17.4.4.8.4. By Technology

17.4.4.8.5. By Application

17.4.4.8.6. By Customer

17.4.5. Italy

17.4.5.1. Market Share Analysis

17.4.5.2. Market Size and Forecast

17.4.5.3. By Product

17.4.5.4. By Technology

17.4.5.5. By Application

17.4.5.6. By Customer

17.4.5.7. Milan

17.4.5.7.1. Market Share Analysis

17.4.5.7.2. Market Size and Forecast

17.4.5.7.3. By Product

17.4.5.7.4. By Technology

17.4.5.7.5. By Application

17.4.5.7.6. By Customer

17.4.6. Switzerland

17.4.6.1. Market Share Analysis

17.4.6.2. Market Size and Forecast

17.4.6.3. By Product

17.4.6.4. By Technology

17.4.6.5. By Application

17.4.6.6. By Customer

17.4.6.7. Zurich

17.4.6.7.1. Market Share Analysis

17.4.6.7.2. Market Size and Forecast

17.4.6.7.3. By Product

17.4.6.7.4. By Technology

17.4.6.7.5. By Application

17.4.6.7.6. By Customer

18. Asia-Pacific Market Analysis and Forecast (2026–2030)

18.1. Introduction

18.2. Market Share Analysis

18.3. Market Size and Forecast

18.4. Market Size and Forecast, By Geography

18.4.1. China

18.4.1.1. Market Share Analysis

18.4.1.2. Market Size and Forecast

18.4.1.3. By Product

18.4.1.4. By Technology

18.4.1.5. By Application

18.4.1.6. By Customer

18.4.1.7. Beijing

18.4.1.7.1. Market Share Analysis

18.4.1.7.2. Market Size and Forecast

18.4.1.7.3. By Product

18.4.1.7.4. By Technology

18.4.1.7.5. By Application

18.4.1.7.6. By Customer

18.4.1.8. Shanghai

18.4.1.8.1. Market Share Analysis

18.4.1.8.2. Market Size and Forecast

18.4.1.8.3. By Product

18.4.1.8.4. By Technology

18.4.1.8.5. By Application

18.4.1.8.6. By Customer

18.4.2. Japan

18.4.2.1. Market Share Analysis

18.4.2.2. Market Size and Forecast

18.4.2.3. By Product

18.4.2.4. By Technology

18.4.2.5. By Application

18.4.2.6. By Customer

18.4.2.7. Tokyo

18.4.2.7.1. Market Share Analysis

18.4.2.7.2. Market Size and Forecast

18.4.2.7.3. By Product

18.4.2.7.4. By Technology

18.4.2.7.5. By Application

18.4.2.7.6. By Customer

18.4.2.8. Osaka

18.4.2.8.1. Market Share Analysis

18.4.2.8.2. Market Size and Forecast

18.4.2.8.3. By Product

18.4.2.8.4. By Technology

18.4.2.8.5. By Application

18.4.2.8.6. By Customer

18.4.3. South Korea

18.4.3.1. Market Share Analysis

18.4.3.2. Market Size and Forecast

18.4.3.3. By Product

18.4.3.4. By Technology

18.4.3.5. By Application

18.4.3.6. By Customer

18.4.3.7. Seoul

18.4.3.7.1. Market Share Analysis

18.4.3.7.2. Market Size and Forecast

18.4.3.7.3. By Product

18.4.3.7.4. By Technology

18.4.3.7.5. By Application

18.4.3.7.6. By Customer

18.4.4. India

18.4.4.1. Market Share Analysis

18.4.4.2. Market Size and Forecast

18.4.4.3. By Product

18.4.4.4. By Technology

18.4.4.5. By Application

18.4.4.6. By Customer

18.4.4.7. Delhi NCR

18.4.4.7.1. Market Share Analysis

18.4.4.7.2. Market Size and Forecast

18.4.4.7.3. By Product

18.4.4.7.4. By Technology

18.4.4.7.5. By Application

18.4.4.7.6. By Customer

18.4.4.8. Mumbai

18.4.4.8.1. Market Share Analysis

18.4.4.8.2. Market Size and Forecast

18.4.4.8.3. By Product

18.4.4.8.4. By Technology

18.4.4.8.5. By Application

18.4.4.8.6. By Customer

18.4.4.9. Bengaluru

18.4.4.9.1. Market Share Analysis

18.4.4.9.2. Market Size and Forecast

18.4.4.9.3. By Product

18.4.4.9.4. By Technology

18.4.4.9.5. By Application

18.4.4.9.6. By Customer

18.4.5. Australia

18.4.5.1. Market Share Analysis

18.4.5.2. Market Size and Forecast

18.4.5.3. By Product

18.4.5.4. By Technology

18.4.5.5. By Application

18.4.5.6. By Customer

18.4.5.7. Sydney

18.4.5.7.1. Market Share Analysis

18.4.5.7.2. Market Size and Forecast

18.4.5.7.3. By Product

18.4.5.7.4. By Technology

18.4.5.7.5. By Application

18.4.5.7.6. By Customer

18.4.5.8. Melbourne

18.4.5.8.1. Market Share Analysis

18.4.5.8.2. Market Size and Forecast

18.4.5.8.3. By Product

18.4.5.8.4. By Technology

18.4.5.8.5. By Application

18.4.5.8.6. By Customer

19. Competition Analysis

19.1. Market Positioning Overview

19.1.1. Global MR-Guided Radiotherapy Leaders

19.1.2. Integrated Oncology Imaging Providers

19.1.3. Adaptive Radiotherapy Innovators

19.1.4. Specialized Radiation Therapy Technology Companies

19.2. Competitive Benchmarking Metrics

19.2.1. Installed System Base

19.2.2. Geographic Deployment Footprint

19.2.3. Clinical Partnership Ecosystem

19.2.4. Treatment Planning Capabilities

19.2.5. Service Infrastructure Strength

19.2.6. Research Collaboration Intensity

19.2.7. Software Innovation

19.2.8. Regulatory Approvals

19.3. Strategic Moves

19.3.1. Clinical Collaborations

19.3.2. AI Integration Partnerships

19.3.3. Radiation Oncology Software Expansion

19.3.4. Hospital Deployment Agreements

19.3.5. Precision Oncology Investments

19.3.6. Multi-Center Validation Studies

19.4. Competitive Mapping & Gaps

19.4.1. Considerable Untapped Opportunities in Emerging Oncology Markets

19.4.2. Mid-Tier Cancer Center Penetration Gaps

19.4.3. AI-Assisted Workflow Differentiation

19.4.4. Cost-Optimization Opportunities

19.4.5. Service and Training Expansion Gaps

20. Company Profiles

20.1. ViewRay Systems, Inc.

20.1.1. Company Overview

20.1.2. Headquarters, Ownership and Founding Year

20.1.3. Workforce Estimate

20.1.4. Geographic Footprint

20.1.5. MRI-Guided Radiotherapy Portfolio

20.1.6. Oncology Imaging Capabilities

20.1.7. Adaptive Radiotherapy Offerings

20.1.8. AI and Software Capabilities

20.1.9. Clinical Target Segments

20.1.10. Distribution and GTM Strategy

20.1.11. Strategic Partnerships

20.1.12. R&D Initiatives

20.1.13. Regulatory Certifications

20.1.14. Financial Overview

20.1.15. Recent Developments

20.1.16. SWOT Snapshot

20.2. Elekta

20.2.1. Company Overview

20.2.2. Headquarters, Ownership and Founding Year

20.2.3. Workforce Estimate

20.2.4. Geographic Footprint

20.2.5. MRI-Guided Radiotherapy Portfolio

20.2.6. Oncology Imaging Capabilities

20.2.7. Adaptive Radiotherapy Offerings

20.2.8. AI and Software Capabilities

20.2.9. Clinical Target Segments

20.2.10. Distribution and GTM Strategy

20.2.11. Strategic Partnerships

20.2.12. R&D Initiatives

20.2.13. Regulatory Certifications

20.2.14. Financial Overview

20.2.15. Recent Developments

20.2.16. SWOT Snapshot

20.3. Siemens Healthineers

20.3.1. Company Overview

20.3.2. Headquarters, Ownership and Founding Year

20.3.3. Workforce Estimate

20.3.4. Geographic Footprint

20.3.5. MRI-Guided Radiotherapy Portfolio

20.3.6. Oncology Imaging Capabilities

20.3.7. Adaptive Radiotherapy Offerings

20.3.8. AI and Software Capabilities

20.3.9. Clinical Target Segments

20.3.10. Distribution and GTM Strategy

20.3.11. Strategic Partnerships

20.3.12. R&D Initiatives

20.3.13. Regulatory Certifications

20.3.14. Financial Overview

20.3.15. Recent Developments

20.3.16. SWOT Snapshot

20.4. GE HealthCare

20.4.1. Company Overview

20.4.2. Headquarters, Ownership and Founding Year

20.4.3. Workforce Estimate

20.4.4. Geographic Footprint

20.4.5. MRI-Guided Radiotherapy Portfolio

20.4.6. Oncology Imaging Capabilities

20.4.7. Adaptive Radiotherapy Offerings

20.4.8. AI and Software Capabilities

20.4.9. Clinical Target Segments

20.4.10. Distribution and GTM Strategy

20.4.11. Strategic Partnerships

20.4.12. R&D Initiatives

20.4.13. Regulatory Certifications

20.4.14. Financial Overview

20.4.15. Recent Developments

20.4.16. SWOT Snapshot

20.5. Philips

20.5.1. Company Overview

20.5.2. Headquarters, Ownership and Founding Year

20.5.3. Workforce Estimate

20.5.4. Geographic Footprint

20.5.5. MRI-Guided Radiotherapy Portfolio

20.5.6. Oncology Imaging Capabilities

20.5.7. Adaptive Radiotherapy Offerings

20.5.8. AI and Software Capabilities

20.5.9. Clinical Target Segments

20.5.10. Distribution and GTM Strategy

20.5.11. Strategic Partnerships

20.5.12. R&D Initiatives

20.5.13. Regulatory Certifications

20.5.14. Financial Overview

20.5.15. Recent Developments

20.5.16. SWOT Snapshot

20.6. Varian Medical Systems

20.6.1. Company Overview

20.6.2. Headquarters, Ownership and Founding Year

20.6.3. Workforce Estimate

20.6.4. Geographic Footprint

20.6.5. MRI-Guided Radiotherapy Portfolio

20.6.6. Oncology Imaging Capabilities

20.6.7. Adaptive Radiotherapy Offerings

20.6.8. AI and Software Capabilities

20.6.9. Clinical Target Segments

20.6.10. Distribution and GTM Strategy

20.6.11. Strategic Partnerships

20.6.12. R&D Initiatives

20.6.13. Regulatory Certifications

20.6.14. Financial Overview

20.6.15. Recent Developments

20.6.16. SWOT Snapshot

20.7. Accuray Incorporated

20.7.1. Company Overview

20.7.2. Headquarters, Ownership and Founding Year

20.7.3. Workforce Estimate

20.7.4. Geographic Footprint

20.7.5. MRI-Guided Radiotherapy Portfolio

20.7.6. Oncology Imaging Capabilities

20.7.7. Adaptive Radiotherapy Offerings

20.7.8. AI and Software Capabilities

20.7.9. Clinical Target Segments

20.7.10. Distribution and GTM Strategy

20.7.11. Strategic Partnerships

20.7.12. R&D Initiatives

20.7.13. Regulatory Certifications

20.7.14. Financial Overview

20.7.15. Recent Developments

20.7.16. SWOT Snapshot

20.8. Canon Medical Systems

20.8.1. Company Overview

20.8.2. Headquarters, Ownership and Founding Year

20.8.3. Workforce Estimate

20.8.4. Geographic Footprint

20.8.5. MRI-Guided Radiotherapy Portfolio

20.8.6. Oncology Imaging Capabilities

20.8.7. Adaptive Radiotherapy Offerings

20.8.8. AI and Software Capabilities

20.8.9. Clinical Target Segments

20.8.10. Distribution and GTM Strategy

20.8.11. Strategic Partnerships

20.8.12. R&D Initiatives

20.8.13. Regulatory Certifications

20.8.14. Financial Overview

20.8.15. Recent Developments

20.8.16. SWOT Snapshot

20.9. Brainlab

20.9.1. Company Overview

20.9.2. Headquarters, Ownership and Founding Year

20.9.3. Workforce Estimate

20.9.4. Geographic Footprint

20.9.5. MRI-Guided Radiotherapy Portfolio

20.9.6. Oncology Imaging Capabilities

20.9.7. Adaptive Radiotherapy Offerings

20.9.8. AI and Software Capabilities

20.9.9. Clinical Target Segments

20.9.10. Distribution and GTM Strategy

20.9.11. Strategic Partnerships

20.9.12. R&D Initiatives

20.9.13. Regulatory Certifications

20.9.14. Financial Overview

20.9.15. Recent Developments

20.9.16. SWOT Snapshot

20.10. RaySearch Laboratories

20.10.1. Company Overview

20.10.2. Headquarters, Ownership and Founding Year

20.10.3. Workforce Estimate

20.10.4. Geographic Footprint

20.10.5. MRI-Guided Radiotherapy Portfolio

20.10.6. Oncology Imaging Capabilities

20.10.7. Adaptive Radiotherapy Offerings

20.10.8. AI and Software Capabilities

20.10.9. Clinical Target Segments

20.10.10. Distribution and GTM Strategy

20.10.11. Strategic Partnerships

20.10.12. R&D Initiatives

20.10.13. Regulatory Certifications

20.10.14. Financial Overview

20.10.15. Recent Developments

20.10.16. SWOT Snapshot

20.11. IBA Radiopharma Solutions

20.11.1. Company Overview

20.11.2. Headquarters, Ownership and Founding Year

20.11.3. Workforce Estimate

20.11.4. Geographic Footprint

20.11.5. MRI-Guided Radiotherapy Portfolio

20.11.6. Oncology Imaging Capabilities

20.11.7. Adaptive Radiotherapy Offerings

20.11.8. AI and Software Capabilities

20.11.9. Clinical Target Segments

20.11.10. Distribution and GTM Strategy

20.11.11. Strategic Partnerships

20.11.12. R&D Initiatives

20.11.13. Regulatory Certifications

20.11.14. Financial Overview

20.11.15. Recent Developments

20.11.16. SWOT Snapshot

20.12. Mevion Medical Systems

20.12.1. Company Overview

20.12.2. Headquarters, Ownership and Founding Year

20.12.3. Workforce Estimate

20.12.4. Geographic Footprint

20.12.5. MRI-Guided Radiotherapy Portfolio

20.12.6. Oncology Imaging Capabilities

20.12.7. Adaptive Radiotherapy Offerings

20.12.8. AI and Software Capabilities

20.12.9. Clinical Target Segments

20.12.10. Distribution and GTM Strategy

20.12.11. Strategic Partnerships

20.12.12. R&D Initiatives

20.12.13. Regulatory Certifications

20.12.14. Financial Overview

20.12.15. Recent Developments

20.12.16. SWOT Snapshot

20.13. Panacea Medical Technologies

20.13.1. Company Overview

20.13.2. Headquarters, Ownership and Founding Year

20.13.3. Workforce Estimate

20.13.4. Geographic Footprint

20.13.5. MRI-Guided Radiotherapy Portfolio

20.13.6. Oncology Imaging Capabilities

20.13.7. Adaptive Radiotherapy Offerings

20.13.8. AI and Software Capabilities

20.13.9. Clinical Target Segments

20.13.10. Distribution and GTM Strategy

20.13.11. Strategic Partnerships

20.13.12. R&D Initiatives

20.13.13. Regulatory Certifications

20.13.14. Financial Overview

20.13.15. Recent Developments

20.13.16. SWOT Snapshot

20.14. Hitachi High-Tech

20.14.1. Company Overview

20.14.2. Headquarters, Ownership and Founding Year

20.14.3. Workforce Estimate

20.14.4. Geographic Footprint

20.14.5. MRI-Guided Radiotherapy Portfolio

20.14.6. Oncology Imaging Capabilities

20.14.7. Adaptive Radiotherapy Offerings

20.14.8. AI and Software Capabilities

20.14.9. Clinical Target Segments

20.14.10. Distribution and GTM Strategy

20.14.11. Strategic Partnerships

20.14.12. R&D Initiatives

20.14.13. Regulatory Certifications

20.14.14. Financial Overview

20.14.15. Recent Developments

20.14.16. SWOT Snapshot

20.15. Fujifilm Healthcare

20.15.1. Company Overview

20.15.2. Headquarters, Ownership and Founding Year

20.15.3. Workforce Estimate

20.15.4. Geographic Footprint

20.15.5. MRI-Guided Radiotherapy Portfolio

20.15.6. Oncology Imaging Capabilities

20.15.7. Adaptive Radiotherapy Offerings

20.15.8. AI and Software Capabilities

20.15.9. Clinical Target Segments

20.15.10. Distribution and GTM Strategy

20.15.11. Strategic Partnerships

20.15.12. R&D Initiatives

20.15.13. Regulatory Certifications

20.15.14. Financial Overview

20.15.15. Recent Developments

20.15.16. SWOT Snapshot

20.16. Shimadzu Corporation

20.16.1. Company Overview

20.16.2. Headquarters, Ownership and Founding Year

20.16.3. Workforce Estimate

20.16.4. Geographic Footprint

20.16.5. MRI-Guided Radiotherapy Portfolio

20.16.6. Oncology Imaging Capabilities

20.16.7. Adaptive Radiotherapy Offerings

20.16.8. AI and Software Capabilities

20.16.9. Clinical Target Segments

20.16.10. Distribution and GTM Strategy

20.16.11. Strategic Partnerships

20.16.12. R&D Initiatives

20.16.13. Regulatory Certifications

20.16.14. Financial Overview

20.16.15. Recent Developments

20.16.16. SWOT Snapshot

Frequently Asked Questions

The market is estimated at approximately USD 0.40 Billion in 2025 and is projected to reach approximately USD 0.70 Billion by 2030, expanding at a compound annual growth rate of roughly 12 percent. The estimate is a derivation from the wider radiotherapy category using labelled analyst assumptions.

They are radiotherapy delivery platforms that integrate magnetic resonance imaging with the treatment unit, together with the planning, adaptive workflow, software and service layers around them. This report describes the category strictly as a market segment and makes no claim about the performance or outcomes of any system.

Five system types are tracked: MR-Linac systems, hybrid MRI-radiotherapy platforms, MRI-guided stereotactic radiotherapy systems, adaptive radiation therapy platforms and MRI-integrated treatment planning ecosystems, each assessed across low-field, mid-field and high-field configurations.

North America forms the largest regional concentration, while Asia-Pacific forms the fastest-growing, tied to expanding tertiary cancer hospital capacity and first-time system specification. Europe is the third region covered.

Growth is driven by interest in online adaptive radiotherapy, expansion of stereotactic and hypofractionated programs, wider use of AI-assisted contouring and planning software, and investment by academic and comprehensive cancer centers in reference-site technology.

The main restraints are high capital cost and infrastructure requirements, procurement cycles of 9 to 24 months, reimbursement uncertainty and budget constraints, and the workflow and staffing demands of adaptive sessions.

Buyers are mainly academic medical centers, comprehensive cancer centers, university hospitals, specialty radiation oncology clinics, multi-site oncology networks and research institutions, purchasing through direct capital purchase, leasing, vendor-managed service contracts or long-term infrastructure partnerships.

They are the three magnetic field strength categories used to segment systems by the magnet class their platform is built around. They are applied as market categories only, and this report makes no comparison of image quality or treatment performance between them.

Inquire Before Buying Request Free Sample Ask For Discount

Why this estimate is a derivation from a parent category.

Genuine attempts were made to find a published estimate specific to MRI-guided radiation therapy systems as scoped in this report. None was found at that scope. Published headline figures do exist for the broader radiotherapy category, but they do not break out MRI-guided platforms, so the size estimate here is a transparent top-down derivation from that parent category, not a quotation of an external figure. Every ratio applied below is an analyst assumption and is labelled as such.

Parent category anchor.

Published headline estimates for the global radiotherapy category point to a market of approximately USD 7.6 Billion in 2025, approximately USD 8.0 Billion in 2026 and approximately USD 10.7 Billion by 2031, a growth rate of roughly 6.0 percent a year. Only headline figures were reviewed, not the underlying methodology or the exact boundary between equipment, software and service revenue, so the anchor is treated as an indicative level rather than a precise value.

Scope adjustment applied as analyst assumptions.

An analyst assumption that approximately 80 percent of the parent category relates to external beam equipment and its related content reduces the anchor to approximately USD 6.1 Billion. A second analyst assumption sets the MRI-guided proportion of that value at approximately 5.5 percent, informed by a 2024 trade commentary from the medical physics community indicating that MR-Linac systems were only about 2 percent of treatment systems, and lifted above that unit proportion because each MRI-guided system carries a higher value than a conventional unit. This gives approximately USD 0.33 Billion. A third analyst assumption adds approximately 20 percent for planning software, integration and service content, giving approximately USD 0.40 Billion for 2025. None of the three ratios is taken from a published source.

Forecast basis and principal sensitivity.

The forecast applies an analyst-assumed growth rate of approximately 12 percent a year, double the parent category's headline growth, reflecting the smaller installed base of MRI-guided platforms, expanding adaptive software content and new center specification in Asia-Pacific, tempered by long procurement cycles and capital constraints. Applied to the 2025 base, this gives approximately USD 0.70 Billion in 2030. The MRI-guided proportion is the material sensitivity: a change of one percentage point moves the 2025 base by roughly USD 70 Million, and a growth rate two points higher or lower moves the 2030 figure by roughly USD 60 to 65 Million.

Frequently Asked Questions

The market is estimated at approximately USD 0.40 Billion in 2025 and is projected to reach approximately USD 0.70 Billion by 2030, expanding at a compound annual growth rate of roughly 12 percent. The estimate is a derivation from the wider radiotherapy category using labelled analyst assumptions.

They are radiotherapy delivery platforms that integrate magnetic resonance imaging with the treatment unit, together with the planning, adaptive workflow, software and service layers around them. This report describes the category strictly as a market segment and makes no claim about the performance or outcomes of any system.

Five system types are tracked: MR-Linac systems, hybrid MRI-radiotherapy platforms, MRI-guided stereotactic radiotherapy systems, adaptive radiation therapy platforms and MRI-integrated treatment planning ecosystems, each assessed across low-field, mid-field and high-field configurations.

North America forms the largest regional concentration, while Asia-Pacific forms the fastest-growing, tied to expanding tertiary cancer hospital capacity and first-time system specification. Europe is the third region covered.

Growth is driven by interest in online adaptive radiotherapy, expansion of stereotactic and hypofractionated programs, wider use of AI-assisted contouring and planning software, and investment by academic and comprehensive cancer centers in reference-site technology.

The main restraints are high capital cost and infrastructure requirements, procurement cycles of 9 to 24 months, reimbursement uncertainty and budget constraints, and the workflow and staffing demands of adaptive sessions.

Buyers are mainly academic medical centers, comprehensive cancer centers, university hospitals, specialty radiation oncology clinics, multi-site oncology networks and research institutions, purchasing through direct capital purchase, leasing, vendor-managed service contracts or long-term infrastructure partnerships.

They are the three magnetic field strength categories used to segment systems by the magnet class their platform is built around. They are applied as market categories only, and this report makes no comparison of image quality or treatment performance between them.

Inquire Before Buying Request Free Sample Ask For Discount